Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HPV
MedTech
CareDx expands into cancer testing with $260M Naveris buy
CareDx is making a move into the oncology space, scooping up Massachusetts-based biotech Naveris in a deal worth up to $260 million.
Natalie Missakian
Apr 30, 2026 2:29am
Nykode bets future on cancer trial after losing Genentech pact
Aug 27, 2025 8:25am
PDS reports 39 months OS in phase 2 head and neck cancer trial
Aug 25, 2025 9:00am
BD to study HPV self-collection in underserved Texas communities
Nov 21, 2024 10:45am
GSK drops ph. 2 HPV vaccine over lack of best-in-class potential
Jul 31, 2024 8:06am
FDA approves self-collection screening for HPV, cervical cancer
May 15, 2024 11:03am
